{"filings":[{"id":99307,"accession_number":"0000872589-26-000014","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q1 revenue up 19% to $3.6B; non-GAAP EPS $9.47; gross margin guidance cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3,605M (+19% YoY); GAAP EPS $6.75, non-GAAP EPS $9.47.","EYLEA HD U.S. net sales $468M (+52%); EYLEA HD+EYLEA total U.S. down 10% to $941M.","Dupixent global net sales (Sanofi) up 33% to $4.9B; new approvals for CSU in children and AFRS.","New $3.0B share repurchase authorized; $803M bought back in Q1; dividend $0.94/share.","FY2026 GAAP gross margin guidance reduced to 77%-78% from 79%-80% due to Limerick plant disruption."],"consensus_eps_estimate":null,"consensus_eps_actual":6.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":3605400000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99306,"accession_number":"0001104659-26-040661","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Regeneron expects ~$102M IPR&D charge in Q1 2026, ~$0.81 EPS hit","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Pre-tax acquired IPR&D charge of ~$102M from milestone/up-front payments and equity securities premium.","Charge expected to reduce GAAP and non-GAAP diluted EPS by ~$0.81 each for Q1 2026.","Results are preliminary, subject to closing procedures; actuals may differ.","Regeneron does not forecast such charges due to transaction uncertainty.","Company reiterates non-GAAP measure excludes certain items not viewed as useful."],"consensus_eps_estimate":null,"consensus_eps_actual":6.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":3605400000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115224,"accession_number":"0000872589-26-000004","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q4 rev $3.88B (+3%), GAAP EPS $7.86; Dupixent +34% to $4.9B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue $3.884B (+3% YoY); GAAP diluted EPS $7.86 (vs $8.06 Q4 2024); non-GAAP EPS $11.44 (vs $12.07).","Dupixent global net sales (Sanofi) $4.9B in Q4, +34% YoY; full year $17.8B +26%.","EYLEA HD U.S. net sales $506M (+66%) but total EYLEA franchise fell 28% to $1.1B on competition and patient transition.","FDA approved EYLEA HD for RVO and monthly dosing; new vial filler approved; Libtayo approved as first immunotherapy for adjuvant CSCC.","2026 guidance: GAAP R&D $6.45-6.68B, non-GAAP gross margin 83-84%; quarterly dividend raised to $0.94/share."],"consensus_eps_estimate":null,"consensus_eps_actual":41.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":14342900000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115223,"accession_number":"0001104659-26-002691","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Regeneron expects Q4 IPR&D charge of ~$19M and $60M matching donation charge","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects ~$19M pre-tax IPR&D charge in Q4 2025, reducing GAAP and non-GAAP diluted EPS by ~$0.14.","Records ~$60M SG&A charge for matching donations to Good Days retinal fund in Q4 2025.","Preliminary Q4 and FY2025 financial update provided at J.P. Morgan Healthcare Conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131644,"accession_number":"0000872589-25-000026","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q3'25: Revenue $3.75B (+1%), GAAP EPS $13.62, Non-GAAP EPS $11.83; EYLEA sales down 28%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $3.754B (+1% YoY); GAAP EPS $13.62 (+18%), non-GAAP EPS $11.83 (-5%).","Dupixent global net sales (Sanofi) up 27% to $4.86B; total EYLEA HD+EYLEA U.S. down 28% to $1.11B.","FDA approved Libtayo for adjuvant CSCC; positive Phase 3 data for cemdisiran in myasthenia gravis and DB-OTO gene therapy in hearing loss.","2025 guidance revised: GAAP R&D $5.68-5.75B, GAAP SG&A $2.775-2.845B, gross margin about 82%, ETR about 14%."],"consensus_eps_estimate":null,"consensus_eps_actual":33.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":10458600000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131643,"accession_number":"0001104659-25-096921","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Regeneron expects Q3 2025 pre-tax IPR&D charge of ~$83M, reducing EPS by $0.68","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pre-tax acquired IPR&D charge of ~$83M for Q3 2025, primarily from $80M upfront to Hansoh Pharma.","Charge expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.68 per share.","Preliminary results subject to financial statement closing procedures and may change.","Regeneron does not forecast such IPR&D charges due to uncertainty in timing and magnitude."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148210,"accession_number":"0000872589-25-000017","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q2 revenue $3.68B (+4%), GAAP EPS $12.81, non-GAAP EPS $12.89; Dupixent sales +22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.676B (+4% YoY); GAAP net income $1.392B, GAAP EPS $12.81 (+3%); non-GAAP EPS $12.89 (+12%).","Dupixent global net sales (Sanofi) up 22% to $4.34B; EYLEA HD U.S. net sales up 29% to $393M, total EYLEA U.S. down 25% to $1.15B.","FDA approved Lynozyfic (linvoseltamab) for relapsed/refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria.","EYLEA HD PDUFA delayed due to FDA filler inspection; odronextamab received CRL; company expects expeditious resolution.","In-licensed late-stage dual GLP-1/GIP agonist from Hansoh; Q2 share repurchases $1.07B; $0.88 dividend declared."],"consensus_eps_estimate":null,"consensus_eps_actual":20.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":6704300000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166980,"accession_number":"0001104659-25-060637","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Regeneron shareholders elect directors, approve board declassification; two supermajority amendments fail","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors elected: Bassler (87.3M for, 18.6M against), Brown (77.0M for, 28.9M against), Schleifer (99.3M for), Yancopoulos (101.4M for).","Board declassification amendment approved (85.7M for, 20.2M against, 5.6M broker non-votes).","Proposal to amend Class A stock conversion supermajority vote failed (0 Class A for, 18.1M against).","Proposal to remove 80% supermajority for director removal also failed (85.5M for, 20.4M against, not meeting required vote).","Advisory vote on executive compensation approved (98.8M for, 7.1M against); auditor ratification also passed (105.5M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166979,"accession_number":"0001804220-25-000020","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q1 revenue down 4%, non-GAAP EPS falls 14%; lowers gross margin guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 revenue $3.03B (-4% YoY); GAAP EPS $7.27 (+16%), non-GAAP EPS $8.22 (-14%).","Dupixent global net sales (Sanofi) up 19% to $3.67B; EYLEA HD US up 54% but total EYLEA franchise down 26% to $1.04B.","FDA issued CRL for EYLEA HD pre-filled syringe (non-safety, third-party supplier issue) and separate CRL denying extended dosing beyond every 16 weeks.","Lowers 2025 GAAP gross margin guidance to 83%-84%, non-GAAP to 86%-87% (prior 84%-85% and 87%-88%).","Settled EYLEA biosimilar litigation with Biocon; launch precluded until H2 2026; entered 10-year manufacturing agreement with Fujifilm."],"consensus_eps_estimate":null,"consensus_eps_actual":7.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":3028700000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184363,"accession_number":"0001804220-25-000007","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Regeneron Q4 revenue up 10% to $3.79B; initiates $0.88 quarterly dividend, adds $3B buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $8.06 (-21% YoY); non-GAAP diluted EPS $12.07 (+2% YoY). Full year revenue $14.20B (+8%).","Q4 Dupixent global net sales $3.70B (+15%); EYLEA HD/EYLEA US net sales $1.50B (+2%); Libtayo global $367M (+50%).","Initiated quarterly cash dividend of $0.88/share, payable March 20, 2025. Board authorized additional $3.0B share repurchase (total capacity ~$4.5B).","Regulatory applications submitted for EYLEA HD pre-filled syringe, Dupixent in bullous pemphigoid, linvoseltamab, and odronextamab."],"consensus_eps_estimate":null,"consensus_eps_actual":38.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":14202000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184362,"accession_number":"0001104659-25-002826","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Regeneron reports 2024 prelim EYLEA sales $6B; Libtayo >$1B; Dupixent >1M patients; pipeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EYLEA HD and EYLEA aggregate U.S. net sales $6B for 2024 (+1% YoY); Q4 combined $1.5B (EYLEA HD $305M).","Libtayo exceeded $1B in 2024 annual net sales; Phase 3 adjuvant CSCC shows 68% risk reduction vs placebo.","New Truveta collaboration to sequence up to 10M additional individuals; RGC has sequenced ~3M people.","Preliminary Q4 2024 IPR&D charge ~$14M pre-tax, expected to impact GAAP and non-GAAP EPS by ~$0.11.","Dupixent now used by over 1M patients globally; linvoseltamab BLA resubmitted with launch anticipated mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":38.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":14202000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200955,"accession_number":"0001804220-24-000038","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q3 revenue up 11% to $3.72B; GAAP EPS $11.54; Dupixent sales +23%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.72B (+11% YoY); GAAP net income $1.34B, diluted EPS $11.54 (up 30%).","Non-GAAP diluted EPS $12.46 (up 8%); includes $0.43 unfavorable IPR&D charge.","Dupixent global net sales $3.82B (+23%, recorded by Sanofi); EYLEA HD+EYLEA US $1.54B (+3%).","FDA approved Dupixent for COPD in Sept. 2024; positive Phase 3 data for CSU and bullous pemphigoid.","FY 2024 guidance updated: GAAP R&D $5.055-5.145B, SG&A $2.93-3.02B; share repurchases $738M in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":30.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":10412800000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200954,"accession_number":"0001104659-24-106432","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Regeneron expects $56M pre-tax IPR&D charge in Q3 2024, reducing EPS by $0.43","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary $56M pre-tax acquired IPR&D charge expected for Q3 2024 from milestone/up-front payments.","GAAP and non-GAAP diluted EPS expected to be negatively impacted by approximately $0.43.","Charge relates to collaboration and licensing agreement payments; such charges are not forecast.","Q3 2024 financial results are not finalized and subject to closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216968,"accession_number":"0001804220-24-000026","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q2 revenue up 12% to $3.55B, EPS beats; EU approves Dupixent for COPD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $3.55B (+12% YoY); GAAP diluted EPS $12.41 (+46%); non-GAAP diluted EPS $11.56 (+13%).","Dupixent global net sales up 27% to $3.56B; EU approved for COPD; FDA decision expected Sept 27, 2024.","EYLEA HD/EYLEA U.S. sales $1.53B (+2%), including $304M from EYLEA HD.","Libtayo global net sales up 42% to $297M; pipeline progress in obesity, gene therapy, oncology.","New $3B share repurchase authorization; $601M repurchased in Q2; 2024 guidance updated."],"consensus_eps_estimate":null,"consensus_eps_actual":18.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":6692100000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216967,"accession_number":"0001104659-24-078172","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Regeneron expects $24M IPR&D charge in Q2 2024, ~$0.18 EPS hit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Estimated pre-tax acquired IPR&D charge of ~$24 million for Q2 2024.","Charge expected to negatively impact GAAP and non-GAAP EPS by ~$0.18 per diluted share.","Charge relates to up-front payments and equity premium on collaboration and licensing deals.","Results are preliminary and subject to financial close procedures; actual may vary."],"consensus_eps_estimate":null,"consensus_eps_actual":18.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":6692100000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236712,"accession_number":"0001104659-24-073372","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Regeneron shareholders elect directors, approve executive compensation at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class III directors elected: N.A. Coles, K. Guarini, A.F. Ryan, G.L. Sing; Class II director D.P. Schenkein elected.","Ratification of PwC as auditor for FY2024: 111.4M for, 5.3M against, 60.6K abstain.","Advisory vote on executive compensation passed: 106.7M for, 5.6M against, 207.5K abstain, 4.2M broker non-votes.","Non-binding shareholder proposal requesting simple majority voting approved: 85.9M for, 26.4M against, 188.7K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236711,"accession_number":"0001804220-24-000015","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Regeneron Q1 revenue down 1% to $3.15B; Non-GAAP EPS $9.55; new $3B buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $722M ($6.27 diluted EPS) vs $818M ($7.17) YoY; Non-GAAP net income $1,116M ($9.55).","Dupixent global net sales up 24% to $3.08B; EYLEA HD U.S. sales $200M, total EYLEA/HD $1.4B (down 2%).","Libtayo global net sales up 45% to $264M; Sanofi collaboration revenue up 14% to $910M.","Board authorized new $3.0B share repurchase; Q1 repurchases $298M, $1.2B remaining under prior program.","2024 guidance updated: GAAP R&D $4.92-5.17B, GAAP SG&A $2.94-3.09B; gross margin unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":6.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":3145000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":65811650368.07233,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}